ALPS Medical Breakthroughs ETF

SBIO

Market cap $100M

The ALPS Medical Breakthroughs ETF has staged a remarkable comeback, outperforming despite a challenging macro backdrop and small-cap weakness. SBIO benefited from a rebound in FDA drug approvals, positive clinical news, and increased M&A activity as large pharma seeks pipeline replenishment. Risks remain high for SBIO, including sector volatility, unprofitability, sensitivity to interest rates, and potential regulatory or political headwinds.

Sabio Holdings Inc. ( SBIO:CA ) Q3 2025 Earnings Call November 25, 2025 10:00 AM EST Company Participants Aziz Rahimtoola - Co-Founder, CEO & Chairman Sajid Premji - Chief Financial Officer Conference Call Participants Gabriel Leung - Beacon Securities Limited, Research Division Daniel Rosenberg - Paradigm Capital Inc., Research Division Nicholas Cortellucci - Atrium Research Corporation Presentation Operator Good morning, everyone, and welcome to Sabio Holdings Third Quarter 2025 Earnings Call. The financial statements and management discussion and analysis are available on SEDAR+.

Regarding the healthcare sector again disappointing investors in 2025 — the largest ETF addressing the group is up just 11.39% — there are pockets of strength. Those include biotech stocks and the related ETFs.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

In the shifting landscape of ETFs, many funds claim to offer exposure to innovation. Technology plays a key role as a growth industry and a driver for performance across the economy overall, as well.

Looking to add some diversification and upside to your equities allocation? While the broader tech space has largely relied on just a handful of names, smaller subcategories in innovative tech also have a role to play.

The tech ETF space offers plenty of important questions for investors.

Biotech stocks and related ETFs are in the midst of a lengthy period of underperformance. For the three years ending July 9, the largest ETF in the category returned just 11%.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

It's understandable investors are frustrated with broader measures of small-cap equities. They've been hearing about the possibility of smaller stocks outperforming larger counterparts for a while.